ImmunityBio, Inc. (NASDAQ:IBRX) Shares Acquired by Courier Capital LLC

Courier Capital LLC lifted its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 33.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,000 shares of the company’s stock after purchasing an additional 10,000 shares during the quarter. Courier Capital LLC’s holdings in ImmunityBio were worth $120,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Stephens Inc. AR acquired a new stake in shares of ImmunityBio during the fourth quarter worth $26,000. Thrive Wealth Management LLC acquired a new position in ImmunityBio in the first quarter valued at $30,000. Cibc World Markets Corp acquired a new position in ImmunityBio in the fourth quarter valued at $35,000. Maia Wealth LLC acquired a new position in ImmunityBio in the fourth quarter valued at $37,000. Finally, GF Fund Management CO. LTD. acquired a new position in ImmunityBio in the fourth quarter valued at $37,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Price Performance

NASDAQ:IBRX opened at $3.34 on Wednesday. The business’s 50-day moving average is $2.60 and its two-hundred day moving average is $3.01. ImmunityBio, Inc. has a 12 month low of $1.83 and a 12 month high of $7.63. The firm has a market capitalization of $2.95 billion, a PE ratio of -3.63 and a beta of 0.14.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The business had revenue of $16.52 million during the quarter, compared to the consensus estimate of $17.50 million. Equities analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and issued a $30.00 target price on shares of ImmunityBio in a report on Tuesday, June 3rd. Piper Sandler upgraded ImmunityBio from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $4.25 to $5.00 in a report on Tuesday, May 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of ImmunityBio in a report on Wednesday, June 4th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $12.25.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.